Quanterix Corp
Formerly Digital Genomics, Inc.
Quanterix Corp is listed today as Quanterix Corporation: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2019 | $6 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jun 2017 | $9 M | No. 5 | $2 to $10 million | equity | SEC | |
| Mar 2016 | $46 M | No. 4 | $10 to $50 million | equity | SEC | |
| Mar 2012 | $2 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Aug 2011 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Sep 2010 | $3 M | No. 1 | $2 to $10 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Quanterix Corporation, its revenue in fiscal 2025 came from these product and service lines: Consumable and other products $75.08 million (54%), Simoa $71.03 million (51%), Service and Other Revenue $44.21 million (32%), Simoa $32.39 million (23%), Research services $25.98 million (19%).
Annual report (SEC XBRL) · Dec 2025
Quanterix Corp chose not to state its revenue in its newest notice of a funding round (Jul 2019).
SEC Form D · Jul 2019
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jul 2019
Products and services#
No products or services of Quanterix Corp are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund VIII Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Arch Venture Fund VI LP | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| ARCH Venture Partners VIII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Arch Venture Partners VI LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Arch Venture Partners VI LP | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bain Capital Venture Fund 2005, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bain Capital Venture Investors, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bain Capital Venture Partners 2005, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| BCIP Associates III | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| BCIP Associates III-B | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| BCIP Associates III-B, LLC | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| BCIP Associates III, LLC | Other | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| bioMerieux/ADR | Person | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| David R. Walt | Person | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Flagship Ventures Fund 2004 L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Flagship Ventures General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Marijn E. Dekkers | Person | not stated | not stated | Held Series D-1 preferred stock, director (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 15 investors.
Largest shareholders today
Institutions holding Quanterix Corporation shares, as of Sep 30, 2026.
- BlackRock, Inc.$14 M7.92%
- Blue Water Life Science Advisors, LP$13 M7.32%
- First Eagle Investment Management, LLC$8 M4.62%
- Portolan Capital Management, LLC$7 M3.88%
- Vanguard Capital Management LLC$7 M3.79%
- Lionhunter Capital Management, LLC$6 M3.63%
- Marshall Wace, LLP$4 M2.52%
- Geode Capital Management, LLC$4 M2.39%
- State Street Corp$3 M1.90%
- Prosight Management, LP$3 M1.74%
- AQR Capital Management LLC$3 M1.66%
- Citadel Advisors LLC$3 M1.56%
- Morgan Stanley$2 M1.36%
- Tikvah Management LLC$2 M1.20%
- Goldman Sachs Group Inc$2 M1.11%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Amol Kevin Chaubal | Executive officer | Jul 2019 |
| E. Kevin Hrusovsky | Executive officer | Jul 2019 |
| Ernest Orticerio | Executive officer | Jun 2017 |
| Joseph Driscoll | Executive officer | Jun 2017 |
| Kevin Hrusovsky | Executive officer | Jun 2017 |
| Ernest L. Oriticerio | Executive officer | Mar 2012 |
| Martin Madaus | Executive officer | Mar 2012 |
| Phillip L. Gardella | Executive officer | Aug 2011 |
| David Okrongly | Executive officer | Oct 2010 |
| David R. Walt | Director | Jul 2019 |
| Douglas G. Cole | Director | Jul 2019 |
| E. Kevin Hrusovsky | Director | Jul 2019 |
| John M. Connolly | Director | Jul 2019 |
| Keith L. Crandell | Director | Jul 2019 |
| Marijn L. Dekkers | Director | Jul 2019 |
| Martin D. Madaus | Director | Jul 2019 |
| Paul M. Meister | Director | Jul 2019 |
| David Walt | Director | Jun 2017 |
| Dennis Sandstedt | Director | Jun 2017 |
| Douglas Cole | Director | Jun 2017 |
| John Connolly | Director | Jun 2017 |
| Keith Crandell | Director | Jun 2017 |
| Kevin Hrusovsky | Director | Jun 2017 |
| Marijn Dekkers | Director | Jun 2017 |
| Martin Madaus | Director | Jun 2017 |
| Paul Meister | Director | Jun 2017 |
| David L. Walt | Director | Mar 2012 |
| James L. Nahirny | Director | Mar 2012 |
| David Okrongly | Director | Oct 2010 |
About
Company in Lexington, United States.
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.